We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Rocket Reports 100 Percent Survival in Rare Pediatric Immunodeficiency Trial
Rocket Reports 100 Percent Survival in Rare Pediatric Immunodeficiency Trial
Rocket Pharmaceuticals reported that its trial of a gene therapy targeted toward an aggressive and fatal rare disease in children had a 100 percent survival rate at one year — and the company expects to file for regulatory approval of the treatment in the first half of 2023.